- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01736826
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies
The primary objective of this study is to demonstrate that plasma concentrations of nucleosomes and free DNA differ between three groups:
- pregnant patients with complications typical of placental insufficiency or venous thrombosis (group P),
- healthy women (Group T1) and
- healthy pregnant women (Group T2).
연구 개요
상태
상세 설명
Our secondary objectives include the following:
- To describe, in 15 healthy, non-pregnant women changes in plasma concentrations of nucleosomes and free DNA over 3 months.
- To describe, in 15 pregnant women (without complications), changes in plasma concentrations of nucleosomes and free DNA over the last 7 months of pregnancy
- To show that plasma concentrations of nucleosomes and free DNA, in patients with complicated pregnancies differ according to the nature of the complication
- To show that a relationship exists between the concentrations of nucleosomes, free DNA, and total granulocyte microparticles (and trophoblast particles for pregnant women)
- To evaluate the relationship between nucleosome concentrations, free DNA concentrations and circulating leukocyte populations
- To evaluate the relationship between nucleosome concentrations, free DNA concentrations and hemostasis markers
- To describe changes in hemostasis markers throughout pregnancy
- To evaluate the relationship between nucleosome concentrations, free DNA concentrations and the angiogenic marker CD146
- To add to the Nîmes University Hospital biological collections.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Nîmes Cedex 9, 프랑스, 30029
- CHU de Nimes - Hopital Universitaire Caremeau
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population includes three groups:
Group P: 100 pregnant women with complications typical of placental vascular disease or venous thromboembolism.
Group T1: 30 non-pregnant, healthy volunteers
- The first 15 patients from group T1 will form group T1x. The latter group has two months of additional follow up.
Group T2: 50 pregnant, healthy volunteers
- The first 15 patients from group T2 will form group T2x. The latter group has 7 months of follow-up during pregnancy.
설명
Inclusion Criteria for all patients:
- The patient must have given her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
Inclusion Criteria for patients in group P:
- The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism)
Inclusion Criteria for patients in group T1:
- The patient is available for 3 months of follow-up
- The patient is a non-pregnant healthy volunteer
- No identifiable chronic pathologies
- No history of neoplastic disease
- No history of chronic infectious disease
- No acute disease (such as benign infection), now or within the past two weeks
Inclusion Criteria for patients in group T2:
- The patient is available for 7 months of follow-up
- The patient is pregnant, with no identifiable pregnancy complications
- No identifiable chronic pathologies
- No history of neoplastic disease
- No history of chronic infectious disease
- No acute disease (such as benign infection), now or within the past two weeks
Exclusion Criteria for all patients:
- The patient is participating in another study (with the exception of the following studies: PAPILLO-PMA (2013-A00538-37), ElastoMAP (2013-A01148-37), ElastoDéclenche (2014-A00828-39), LXRs (2009-A00968-49), Bakri (2013-A00914-41), OASIS 2 (2013-A00022-43)).
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient cannot read French
- The patient is receiving hormonal ovarian stimulation in the context of medically assisted procreation
- Impossible to perform venipuncture under good conditions
- New complication or pathology during the study (except for pregnancy complications in group P)
Exclusion Criteria for group P:
- Twin or multiple pregnancy
- The patient is participating in another study (with the exception of those mentioned in the exclusion criteria for all patients and the DG Postpartum study (2013-A00277-38)
Exclusion Criteria for group T1:
- The patient is pregnant
- The patient is breast feeding
- The patient has given birth within the last 3 months
- Known history of chronic disease
- History of treated neoplastic disease
- Acute disease within the past two weeks (includes benign disease)
Exclusion Criteria for group T2:
- Pregnancy with complications
- Known history of chronic disease
- History of treated neoplastic disease
- Acute disease within the past two weeks (includes benign disease)
- Twin or multiple pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Group P: pregnancy w/complications
The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism). 100 patients will be included. Interventions to be administered: Bloodwork, baseline |
36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
|
Group T1: Healthy volunteers
Healthy volunteers with no history of chronic or neoplastic disease. 30 healthy volunteers will be included. Interventions to be administered: Bloodwork, baseline |
36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
|
Group T2: Pregnancy, no complications
Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease. 50 pregnant volunteers will be included. Interventions to be administered: Bloodwork, baseline |
36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
|
Group T1x: 15 Healthy volunteers
15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up. Interventions to be administered: Blood work, Months 1 & 2 |
36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
36 ml of blood are drawn at 1 & 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
|
Group T2x: 15 Pregnancy, no complications
15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy. Interventions to be administered: Bloodwork, Months -1 to -6 |
36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Total plasma concentration of free DNA (ng/ml)
기간: Base line (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
Base line (day 0)
|
Total plasma concentration of nucleosomes (AU)
기간: Base line (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth
|
Base line (day 0)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Hemoglobin (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Platelets (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Leukocytes (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Polynuclear neutrophils(g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Mean corpuscular volume (fL)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Monocytes (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Mean corpuscular hemoglobin (pg/GR)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Lymphocytes (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Polynuclear eosinophils (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Polynuclear basophils (g/l)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
D-dimers (ng/ml)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Fibrin monomers (ng/ml)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Trophoblast microparticles (%)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Angiogenic marker CD146 (ng/ml)
기간: baseline (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
baseline (day 0)
|
Hemoglobin (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Platelets (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Leukocytes (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Polynuclear neutrophils(g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Mean corpuscular volume (fL)
기간: 1 month
|
For group T1x only
|
1 month
|
Monocytes (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Mean corpuscular hemoglobin (pg/GR)
기간: 1 month
|
For group T1x only
|
1 month
|
Lymphocytes (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Polynuclear eosinophils (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
Polynuclear basophils (g/l)
기간: 1 month
|
For group T1x only
|
1 month
|
D-dimers (ng/ml)
기간: 1 month
|
For group T1x only
|
1 month
|
Fibrin monomers (ng/ml)
기간: 1 month
|
For group T1x only
|
1 month
|
Trophoblast microparticles (%)
기간: 1 month
|
For group T1x only
|
1 month
|
Angiogenic marker CD146 (ng/ml)
기간: 1 month
|
For group T1x only
|
1 month
|
Total plasma concentration of free DNA (ng/ml)
기간: 1 month
|
For group T1x only
|
1 month
|
Total plasma concentration of nucleosomes (AU)
기간: 1 month
|
For group T1x only
|
1 month
|
Hemoglobin (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Platelets (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Leukocytes (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Polynuclear neutrophils(g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Mean corpuscular volume (fL)
기간: 2 months
|
For group T1x only
|
2 months
|
Monocytes (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: 2 months
|
For group T1x only
|
2 months
|
Lymphocytes (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Polynuclear eosinophils (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
Polynuclear basophils (g/l)
기간: 2 months
|
For group T1x only
|
2 months
|
D-dimers (ng/ml)
기간: 2 months
|
For group T1x only
|
2 months
|
Fibrin monomers (ng/ml)
기간: 2 months
|
For group T1x only
|
2 months
|
Trophoblast microparticles (%)
기간: 2 months
|
For group T1x only
|
2 months
|
Angiogenic marker CD146 (ng/ml)
기간: 2 months
|
For group T1x only
|
2 months
|
Total plasma concentration of free DNA (ng/ml)
기간: 2 months
|
For group T1x only
|
2 months
|
Total plasma concentration of nucleosomes (AU)
기간: 2 months
|
For group T1x only
|
2 months
|
Hemoglobin (g/l)
기간: -1 months
|
For group T2x only
|
-1 months
|
Hemoglobin (g/l)
기간: -2 months
|
For group T2x only
|
-2 months
|
Hemoglobin (g/l)
기간: -3 months
|
For group T2x only
|
-3 months
|
Hemoglobin (g/l)
기간: -4 months
|
For group T2x only
|
-4 months
|
Hemoglobin (g/l)
기간: -5 months
|
For group T2x only
|
-5 months
|
Hemoglobin (g/l)
기간: -6 months
|
For group T2x only
|
-6 months
|
Platelets (g/l)
기간: -1 months
|
For group T2x only
|
-1 months
|
Platelets (g/l)
기간: -2 months
|
For group T2x only
|
-2 months
|
Platelets (g/l)
기간: -3 months
|
For group T2x only
|
-3 months
|
Platelets (g/l)
기간: -4 months
|
For group T2x only
|
-4 months
|
Platelets (g/l)
기간: -5 months
|
For group T2x only
|
-5 months
|
Platelets (g/l)
기간: -6 months
|
For group T2x only
|
-6 months
|
Leukocytes (g/l)
기간: -1 months
|
For group T2x only
|
-1 months
|
Leukocytes (g/l)
기간: -2 months
|
For group T2x only
|
-2 months
|
Leukocytes (g/l)
기간: -3 months
|
For group T2x only
|
-3 months
|
Leukocytes (g/l)
기간: -4 months
|
For group T2x only
|
-4 months
|
Leukocytes (g/l)
기간: -5 months
|
For group T2x only
|
-5 months
|
Leukocytes (g/l)
기간: -6 months
|
For group T2x only
|
-6 months
|
Polynuclear neutrophils(g/l)
기간: -1 months
|
For group T2x only
|
-1 months
|
Polynuclear neutrophils(g/l)
기간: -2 months
|
For group T2x only
|
-2 months
|
Polynuclear neutrophils(g/l)
기간: -3 months
|
For group T2x only
|
-3 months
|
Polynuclear neutrophils(g/l)
기간: -4 months
|
For group T2x only
|
-4 months
|
Polynuclear neutrophils(g/l)
기간: -5 months
|
For group T2x only
|
-5 months
|
Polynuclear neutrophils(g/l)
기간: -6 months
|
For group T2x only
|
-6 months
|
Mean corpuscular volume (fL)
기간: -1 months
|
For group T2x only
|
-1 months
|
Mean corpuscular volume (fL)
기간: -2 months
|
For group T2x only
|
-2 months
|
Mean corpuscular volume (fL)
기간: -3 months
|
For group T2x only
|
-3 months
|
Mean corpuscular volume (fL)
기간: -4 months
|
For group T2x only
|
-4 months
|
Mean corpuscular volume (fL)
기간: -5 months
|
For group T2x only
|
-5 months
|
Mean corpuscular volume (fL)
기간: -6 months
|
For group T2x only
|
-6 months
|
Monocytes (g/l)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Monocytes (g/l)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Monocytes (g/l)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Monocytes (g/l)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Monocytes (g/l)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Monocytes (g/l)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Mean corpuscular hemoglobin (pg/GR)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Lymphocytes (g/l)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Lymphocytes (g/l)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Lymphocytes (g/l)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Lymphocytes (g/l)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Lymphocytes (g/l)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Lymphocytes (g/l)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Polynuclear eosinophils (g/l)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Polynuclear eosinophils (g/l)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Polynuclear eosinophils (g/l)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Polynuclear eosinophils (g/l)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Polynuclear eosinophils (g/l)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Polynuclear eosinophils (g/l)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Polynuclear basophils (g/l)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Polynuclear basophils (g/l)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Polynuclear basophils (g/l)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Polynuclear basophils (g/l)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Polynuclear basophils (g/l)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Polynuclear basophils (g/l)
기간: -6 months
|
For group T2x only.
|
-6 months
|
D-dimers (ng/ml)
기간: -1 months
|
For group T2x only.
|
-1 months
|
D-dimers (ng/ml)
기간: -2 months
|
For group T2x only.
|
-2 months
|
D-dimers (ng/ml)
기간: -3 months
|
For group T2x only.
|
-3 months
|
D-dimers (ng/ml)
기간: -4 months
|
For group T2x only.
|
-4 months
|
D-dimers (ng/ml)
기간: -5 months
|
For group T2x only.
|
-5 months
|
D-dimers (ng/ml)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Fibrin monomers (ng/ml)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Fibrin monomers (ng/ml)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Fibrin monomers (ng/ml)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Fibrin monomers (ng/ml)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Fibrin monomers (ng/ml)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Fibrin monomers (ng/ml)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Trophoblast microparticles (%)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Trophoblast microparticles (%)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Trophoblast microparticles (%)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Trophoblast microparticles (%)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Trophoblast microparticles (%)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Trophoblast microparticles (%)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Angiogenic marker CD146 (ng/ml)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Angiogenic marker CD146 (ng/ml)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Angiogenic marker CD146 (ng/ml)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Angiogenic marker CD146 (ng/ml)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Angiogenic marker CD146 (ng/ml)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Angiogenic marker CD146 (ng/ml)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Total plasma concentration of nucleosomes (AU)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Total plasma concentration of nucleosomes (AU)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Total plasma concentration of nucleosomes (AU)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Total plasma concentration of nucleosomes (AU)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Total plasma concentration of nucleosomes (AU)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Total plasma concentration of nucleosomes (AU)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Total plasma concentration of free DNA (ng/ml)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Total plasma concentration of free DNA (ng/ml)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Total plasma concentration of free DNA (ng/ml)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Total plasma concentration of free DNA (ng/ml)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Total plasma concentration of free DNA (ng/ml)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Total plasma concentration of free DNA (ng/ml)
기간: -6 months
|
For group T2x only.
|
-6 months
|
Fibrinogen (g/l)
기간: Base line (day 0)
|
For group P, baseline occurs within the 30 days preceding birth.
For group T1, baseline = time of inclusion.
For group T2, baseline occurs within the 30 days preceding birth.
|
Base line (day 0)
|
Fibrinogen (g/l)
기간: -1 months
|
For group T2x only.
|
-1 months
|
Fibrinogen (g/l)
기간: -2 months
|
For group T2x only.
|
-2 months
|
Fibrinogen (g/l)
기간: -3 months
|
For group T2x only.
|
-3 months
|
Fibrinogen (g/l)
기간: -4 months
|
For group T2x only.
|
-4 months
|
Fibrinogen (g/l)
기간: -5 months
|
For group T2x only.
|
-5 months
|
Fibrinogen (g/l)
기간: -6 months
|
For group T2x only.
|
-6 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Sylvie Bouvier, MD, Centre Hospitalier Universitaire de Nîmes
- 수석 연구원: Eve Mousty, MD, Centre Hospitalier Universitaire de Nîmes
간행물 및 유용한 링크
일반 간행물
- Bouvier S, Traboulsi W, Blois SM, Demattei C, Joshkon A, Mousty E, Nollet M, Paulmyer-Lacroix O, Foucault-Bertaud A, Fortier M, Leroyer AS, Bachelier R, Letouzey V, Alfaidy N, Dignat-George F, Blot-Chabaud M, Gris JC, Bardin N. Soluble CD146 is increased in preeclampsia and interacts with galectin-1 to regulate trophoblast migration through VEGFR2 receptor. F S Sci. 2022 Feb;3(1):84-94. doi: 10.1016/j.xfss.2021.11.002. Epub 2021 Nov 19.
- Bouvier S, Mousty E, Fortier M, Demattei C, Mercier E, Nouvellon E, Chea M, Grosjean F, Letouzey V, Gris JC. Placenta-mediated complications: Nucleosomes and free DNA concentrations differ depending on subtypes. J Thromb Haemost. 2020 Dec;18(12):3371-3380. doi: 10.1111/jth.15105. Epub 2020 Oct 18.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
정맥 혈전증에 대한 임상 시험
-
University Hospital, Strasbourg, France완전한
-
Beijing Friendship Hospital알려지지 않은대장암 환자에서 Perioperiative Venous Thromboembolism(VTE)의 발생률
-
Medical University Innsbruck완전한급성 신장 손상 | 비판적으로 아프다 | 신장 대체 요법 | 지속적 신대체 요법 | 지속적인 Veno-Venous Hemofiltration | 교체액 | 포실륨 | 비포질 | 항응고제 | 지역 구연산염 항응고제오스트리아
Bloodwork, baseline에 대한 임상 시험
-
South Valley University완전한
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)완전한